TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04948294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Channeled blade
Description: In the present group, a tracheal tube was launched in the channel of the blade before tracheal intubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-channeled blade
Description: In the present group, a tracheal tube was not launched in the videolaryngoscope blade before tracheal intubation
Study: NCT03716934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arctic Front Advance® balloon catheter
Description: Cryoablation of bidirectional block of all pulmonary veins

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drug
Description: The drug will be chosen based on the preference of the researcher / responsible physician and current clinical practice guidelines.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Confirm RX heart monitor® (Abbott)
Description: Is a subcutaneous implantable device that provides continuous monitoring of the heart rate for more than 3 years without any effect on cardiac function

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Confirm RX heart monitor® (Abbott)
Description: Is a subcutaneous implantable device that provides continuous monitoring of the heart rate for more than 3 years without any effect on cardiac function
Study: NCT03104348

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: COPD screening
Description: Self-questionnaire with 5 questions Fagerström's test Spirometry
Study: NCT04355949

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serum vitamin D, vitamin B12, folic acid
Description: Serum vitamin D, vitamin B12, and folic acid levels will be assessed

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serum vitamin D, vitamin B12, folic acid
Description: Serum vitamin D, vitamin B12, and folic acid levels will be assessed
Study: NCT01587131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FVH1 - a DNA-based influenza vaccine
Description: 0.9 mg FVH1 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FVH1 - a DNA-based influenza vaccine
Description: 0.9 mg FVH1 vaccine
Study: NCT02055430

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Definitive stone management
Description: (shockwave lithotripsy, chemodissolution therapy, ureteroscopy or open surgery) for clearance of stones.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Definitive stone management
Description: (shockwave lithotripsy, chemodissolution therapy, ureteroscopy or open surgery) for clearance of stones.
Study: NCT04580394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD109
Description: Oral administration before bed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: Oral administration before bed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-oxybutynin
Description: Oral administration before bed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration before bed

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Digit System Substitution Test
Description: a neuropsychological test sensitive to brain damage, dementia, age and depression where numbers are assigned symbols. Under each digit the subject should write down the corresponding symbol as fast as possible. The number of correct symbols within the allowed time is measured.
Study: NCT01587131

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: FVH1 - a DNA-based influenza vaccine
Description: 0.9 mg FVH1 vaccine
Study: NCT04310306

Intervention type: DEVICE
Intervention: Thrombectomy using EmboTrap II
Description: The subjects will receive endovascular treatment for acute stroke according to standard clinical practice. Specifically, using a stent retriever, contact aspiration EmboTrap II. The number of thrombectomy attempts is at the operator's discretion. Combination of balloon guide catheter or intermediate catheter is recommended.
Study: NCT04113824

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trapezuis motion style acupuncture treatment
Description: Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: other Korean medical treatment
Description: acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
Study: NCT04580394

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Digit System Substitution Test
Description: a neuropsychological test sensitive to brain damage, dementia, age and depression where numbers are assigned symbols. Under each digit the subject should write down the corresponding symbol as fast as possible. The number of correct symbols within the allowed time is measured.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Digit System Substitution Test
Description: a neuropsychological test sensitive to brain damage, dementia, age and depression where numbers are assigned symbols. Under each digit the subject should write down the corresponding symbol as fast as possible. The number of correct symbols within the allowed time is measured.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Digit System Substitution Test
Description: a neuropsychological test sensitive to brain damage, dementia, age and depression where numbers are assigned symbols. Under each digit the subject should write down the corresponding symbol as fast as possible. The number of correct symbols within the allowed time is measured.
Study: NCT02276716

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phosphatidylserine
Description: Phosphatidylserine will be titrated starting at 300mg/day dose for two months to 600mg/day dose for 2 months, then 800 mg/day dose for a final 2 month period.
Study: NCT02836535

Intervention type: BEHAVIORAL
Intervention: qualitative interviews

Intervention type: BEHAVIORAL
Intervention: qualitative interviews
Study: NCT04113824

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: other Korean medical treatment
Description: acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
Study: NCT03756740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telerehabilitation and physical therapy
Description: subject will receive the LBP exercises as a video to his/her mobile or e-mail

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: subjects will receive the LBP exercises as printed pictures on paper
Study: NCT01853111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Study: NCT01807715

Intervention type: OTHER
Intervention: survey
Description: Survey before procedure to obtain demographic information and contraceptive information
Study: NCT00679731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-874
Description: 200 mg at week 0 and 4 and 100mg at week 8 and every 4 weeks there after administered as aSQ injection
Study: NCT02839486

Intervention type: OTHER
Intervention: vancomycin pharmacokinetics
Description: vancomycin serial plasmatic and ultrafiltrate samples in order to assess plasmatic and ultrafiltrate drug concentrations

Intervention type: OTHER
Intervention: cefoxitin pharmacokinetics
Description: cefoxitin serial plasmatic and ultrafiltrate samples in order to assess plasmatic and ultrafiltrate drug concentrations
Study: NCT02551393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Blood Presssure Monitoring, Education
Description: Doctors and Nurses in intervention clinic will receive 1 hour briefing + education on the background, scientific basis and detail of the program during lunch time. People from intervention clinics will be invited to attend 2 x 2 hours education group (15-30 subjects / group) ran by clinic nurses and doctors. You will be educated on basic knowledge, management and drug for hypertension in the first session. In the 2nd session, a certified valid Home BP device will be loaned to you for 6-9 months and you will be taught to perform home BP monitoring, record and response to the BP reading accordingly. Upon completion of session 2, you will be arranged for nurse individual follow up after 4-8 weeks to see their progress and monitoring
Study: NCT02752841

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional vitamin D repletion and maintenance
Description: Ergocalciferol (50,000 IU weekly for 12 weeks) for vitamin D repletion, ergocalciferol (50,000 IU monthly) or cholecalciferol (1000 IU daily) for maintenance of vitamin D
Study: NCT00679731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 5.0 to 25 mg weekly
Study: NCT04387136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Sufentanil
Description: 15-30 minutes prior to planned emergence from anesthesia patients will either receive 30 mcg of sublingual sufentanil dispensed by the anesthesia provider.
Study: NCT02628249

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Base protein
Description: 0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Base protein
Description: 0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Base protein
Description: 0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Base protein
Description: 0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sufficient protein
Description: 1.75 g/kg/d protein provided as crystalline amino acid modeled after egg protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Branched chain amino acids
Description: Branched chain amino acids modeled after egg protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential amino acids
Description: Essential amino acids modeled after egg protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Non essential amino acids
Description: Non essential amino acids modeled after egg protein.
Study: NCT01228942

Intervention type: DEVICE
Group type: OTHER
Intervention: COXEN analysis for chemotherapy prediction
Description: Using the affymetrix genechip along with the COXEN algorithm the subject's treatment will be determined

Intervention type: DEVICE
Group type: OTHER
Intervention: COXEN analysis for chemotherapy prediction
Description: Using the affymetrix genechip along with the COXEN algorithm the subject's treatment will be determined
Study: NCT04536337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-000184
Description: Single or multiple doses of ALG-000184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALG-000184
Description: Single or multiple doses of ALG-000184

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single or multiple doses of Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: multiple doses of Entecavir
Study: NCT04693442

Intervention type: OTHER
Intervention: taking of blood, urine and blood samples and objective scar assessment
Description: blood, urine and skin tissue sampling \& scar assessment questionnaires
Study: NCT01763268

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivivac vaccine
Description: Trivalent MMR vaccine
Study: NCT05845294

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Routine care for patients undergoing colorectal cancer stoma

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short-term structured psychological Care
Description: Short-term structured psychological care for colorectal cancer stoma patients based on conventional care
Study: NCT04351230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given IV
Study: NCT01740037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialized outpatient AF Clinic

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study: NCT04351230

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab Emtansine
Description: Given PO
Study: NCT02493426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04253977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEALTH-P2
Description: The HEALTH-P2 curriculum includes evidence based lifestyle change strategies to prevent excess gestational weight gain and postpartum weight retention embedded within and delivered as part of home visits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The Foundational (usual care) curriculum uses a strength-based, solution-focused model to provide parents with child development knowledge and parenting support, empowering parents as their child's first and most influential teacher.
Study: NCT04351230

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Given PO
Study: NCT03035123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic education
Description: Interventional arm
Study: NCT02147535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 10 mg as a single dose followed by one blood sample 3 hours post-dose
Study: NCT01755949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine, 0.6 mg PO BID
Description: Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine, 0.6 mg PO BID
Description: Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo
Study: NCT03886701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine (DOR)
Description: Non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 infection in adults in combination with other antiretroviral agents.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine (RPT)
Description: Rifamycin anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Description: Anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.
Study: NCT01043354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stage-matched intervention
Description: 6 monthly tailored telephone-delivered counseling sessions of transtheoretical model-based counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: framing effects intervention
Description: 6 monthly telephone-delivered counseling sessions based on prospect theory

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: attention placebo intervention
Description: 6 monthly counseling sessions about general health topics
Study: NCT02864537

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Patients were trained to measure INR and dose warfarin
Study: NCT02775552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A&T community-based interventions
Description: 1. Interpersonal communication delivered by health workers and community volunteers at the health post and during home visits to:~   - Increase mothers' knowledge about adequate child feeding practices~2. Interpersonal communication delivered by agricultural extension workers to:~   - Increase fathers' knowledge about nutrition-sensitive agriculture and child feeding~3. Community mobilization activities to:~   * Raise awareness of child feeding practices among community members, and increase support to mothers (enhanced community conversations)~  * Increase mothers' knowledge about preparation of complementary foods (cooking demonstrations)~  * Raise awareness of adequate child feeding during fasting among family and community members (church sermons)~4. Enhanced training of government health and agricultural extension workers in infant and young child feeding to:~   * Improve their ability to provide timely and appropriate information and support to mothers and families

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mass media
Description: Radio campaign - radio drama series, spots, and jingles

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mass media
Description: Radio campaign - radio drama series, spots, and jingles
Study: NCT01755949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine, 0.6 mg PO BID
Description: Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug
Study: NCT04142307

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback Training
Description: Microperimeter biofeedback training as described provides to the patient a variable frequency sound and a luminous stimulus that vary according to the eyes position, thus guides the oculomotor control and fixation stability accordingly.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham - simulated BT
Description: The simulated biofeedback training for Group B involves the following: each session includes presentation of a C10-2 microperimetry program. The procedure involves presentation of a standard LED fixation target (FT) consisting of a small red circle of about 0.76° diameter. Initially the participant will be instructed to stare at the FT circle. Following this stage the participant will be guided to look at the FT and simultaneously to be aware of any flashing lights in the periphery of vision. As performing this task, the participant will actively control the eye movements and similar to computer games, the patient has to identify targets in the peripheral field of vision and respond by pressing a button.
Study: NCT01366066

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous mechanical nerve stimulation
Description: A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the perineum. The stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz.~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous mechanical nerve stimulation
Description: A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the perineum. The stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz.~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks.
Study: NCT01755949

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug
Study: NCT02838342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronomic cyclophosphamide
Description: 50 mg oral tablet, one tablet per day, every day for 6 months; abort if progression or intolerance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Description: 3 months of treatment from the 4th cycle metronomic cyclophosphamide : subcutaneous injection, initial dose of 3 MIU three times a week. The dose may be adjusted as tolerated to achieve a T cell counts greater than 500 / mm3
Study: NCT05468411

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral application of miracle fruit pill
Description: Miracle fruit has a taste modifying function from sourness to sweetness when it is exposed to an acidic environment. To activate the miracle fruit's function, a miracle fruit pill should be orally administered to coat taste buds prior to eating sour food. Thus, participants are instructed to place a miracle fruit pill is on their tongue, and roll the pill around their mouth to allow full contact of the pill with the surface of the oral cavity without chewing until the pill completely dissolved. A miracle fruit pill is administered prior to eating.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral application of miracle fruit pill
Description: Miracle fruit has a taste modifying function from sourness to sweetness when it is exposed to an acidic environment. To activate the miracle fruit's function, a miracle fruit pill should be orally administered to coat taste buds prior to eating sour food. Thus, participants are instructed to place a miracle fruit pill is on their tongue, and roll the pill around their mouth to allow full contact of the pill with the surface of the oral cavity without chewing until the pill completely dissolved. A miracle fruit pill is administered prior to eating.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral application of sugar candy
Description: To simulate the miracle fruit's function as a placebo, a chewable sugar candy that has a similar appearance to miracle fruit pill is orally administered. The same protocol that is used in miracle fruit intervention is followed in this placebo intervention but with a chewable sugar candy. Participants are instructed to place a sugar candy is on their tongue, and roll the candy around their mouth to allow full contact of the candy with the surface of the oral cavity without chewing until the candy completely dissolved. A sugar candy is administered prior to eating.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral application of sugar candy
Description: To simulate the miracle fruit's function as a placebo, a chewable sugar candy that has a similar appearance to miracle fruit pill is orally administered. The same protocol that is used in miracle fruit intervention is followed in this placebo intervention but with a chewable sugar candy. Participants are instructed to place a sugar candy is on their tongue, and roll the candy around their mouth to allow full contact of the candy with the surface of the oral cavity without chewing until the candy completely dissolved. A sugar candy is administered prior to eating.